LY2886721|cas 1262036-50-9|DC Chemicals

Cas No.:	1262036-50-9
Chemical Name:	LY2886721
Synonyms:	LY2886721;N-(3-((4AS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide;N-[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide;LY-2886721;N-[3-[(4aS,7aS)-2-Amino-4a,5-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(7H)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide
SMILES:	FC1C=NC(=CC=1)C(=O)NC2=CC(=C(F)C=C2)[C@@]34[C@H](CSC(N)=N4)COC3
Formula:	C₁₈H₁₆N₄O₂F₂S
M.Wt:	390.40704
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

LY2886721 is an BACE inhibitor used for the treatment of Alzheimer's Disease.IC50 value:Target: BACELY2886721 is a novel potent agent that is used to treat Alzheimer’s Disease in preclinical experiments. LY2886721 is under clinical study. A Safety Study of LY2886721 Multiple Doses is performing in Healthy Subjects.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC9901	Verubecestat (MK-8931)	MK-8931 is a BACE1 inhibitor. MK-8931 binds significantly to β-secretase.
DC5053	LY2886721	LY2886721 is an BACE inhibitor used for the treatment of Alzheimer's Disease.
DC5180	LY2811376	LY2811376 is the first orally available non-peptidicβ-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM.
DC11551	Elenbecestat	Elenbecestat (E2609) is a novel potent, oral BACE1 inhibitor for treatment of Alzheimer's disease..
DC11105	Umibecestat	beta-secretase inhibitor.
DC8400	AZD3839	AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.